230 related articles for article (PubMed ID: 12372883)
21. Predictive value of p53 and pRb immunostaining in locally advanced bladder cancer treated with cystectomy.
Jahnson S; Karlsson MG
J Urol; 1998 Oct; 160(4):1291-6. PubMed ID: 9751338
[TBL] [Abstract][Full Text] [Related]
22. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer.
Stein JP; Ginsberg DA; Grossfeld GD; Chatterjee SJ; Esrig D; Dickinson MG; Groshen S; Taylor CR; Jones PA; Skinner DG; Cote RJ
J Natl Cancer Inst; 1998 Jul; 90(14):1072-9. PubMed ID: 9672255
[TBL] [Abstract][Full Text] [Related]
23. p53 expression predicts progression and poor survival in T1 bladder tumours.
Llopis J; Alcaraz A; Ribal MJ; Solé M; Ventura PJ; Barranco MA; Rodriguez A; Corral JM; Carretero P
Eur Urol; 2000 Jun; 37(6):644-53. PubMed ID: 10828662
[TBL] [Abstract][Full Text] [Related]
24. Prognostic values of p53 and HER-2/neu coexpression in invasive bladder cancer in Taiwan.
Tsai YS; Tzai TS; Chow NH; Yang WH; Tong YC; Lin JS; Chang CC; Cheng HL; Lin YM
Urol Int; 2003; 71(3):262-70. PubMed ID: 14512646
[TBL] [Abstract][Full Text] [Related]
25. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407
[TBL] [Abstract][Full Text] [Related]
26. Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder.
Dekairelle AF; Tombal B; Cosyns JP; Gala JL
Clin Cancer Res; 2005 Jul; 11(13):4724-32. PubMed ID: 16000567
[TBL] [Abstract][Full Text] [Related]
27. Expression of bcl-2 and bcl-X in bladder cancer.
Kirsh EJ; Baunoch DA; Stadler WM
J Urol; 1998 Apr; 159(4):1348-53. PubMed ID: 9507882
[TBL] [Abstract][Full Text] [Related]
28. p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer.
Ahrendt SA; Brown HM; Komorowski RA; Zhu YR; Wilson SD; Erickson BA; Ritch PS; Pitt HA; Demeure MJ
Surgery; 2000 Oct; 128(4):520-30. PubMed ID: 11015084
[TBL] [Abstract][Full Text] [Related]
29. The p53 tumor suppressor gene and nuclear protein: basic science review and relevance in the management of bladder cancer.
Smith ND; Rubenstein JN; Eggener SE; Kozlowski JM
J Urol; 2003 Apr; 169(4):1219-28. PubMed ID: 12629332
[TBL] [Abstract][Full Text] [Related]
30. Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients.
Williams SG; Gandour-Edwards R; Deitch AD; Toscano S; Fan JJ; Sternberg CN; Pansadoro V; Calabrò F; Rossetti A; deVere White RW
Eur Urol; 2001 Apr; 39(4):430-7. PubMed ID: 11306882
[TBL] [Abstract][Full Text] [Related]
31. Can p53 help select patients with invasive bladder cancer for bladder preservation?
Herr HW; Bajorin DF; Scher HI; Cordon-Cardo C; Reuter VE
J Urol; 1999 Jan; 161(1):20-2; discussion 22-3. PubMed ID: 10037358
[TBL] [Abstract][Full Text] [Related]
32. Implications of p53 gene mutations on patient survival in transitional cell carcinoma of the bladder: a long-term study.
Salinas-Sánchez AS; Lorenzo-Romero JG; Giménez-Bachs JM; Sánchez-Sánchez F; Donate-Moreno MJ; Rubio-Del-Campo A; Hernández-Millán IR; Segura-Martín M; Atienzar-Tobarra M; Escribano-Martínez J
Urol Oncol; 2008; 26(6):620-6. PubMed ID: 18367096
[TBL] [Abstract][Full Text] [Related]
33. Reciprocal expression of bcl-2 and p53 oncoproteins in urothelial dysplasia and carcinoma of the urinary bladder.
Li B; Kanamaru H; Noriki S; Yamaguchi T; Fukuda M; Okada K
Urol Res; 1998; 26(4):235-41. PubMed ID: 9759996
[TBL] [Abstract][Full Text] [Related]
34. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer.
Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Isbarn H; Fradet Y; Bastian PJ; Nielsen ME; Capitanio U; Jeldres C; Montorsi F; Lerner SP; Sagalowsky AI; Cote RJ; Lotan Y
J Urol; 2010 Jan; 183(1):68-75. PubMed ID: 19913255
[TBL] [Abstract][Full Text] [Related]
35. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
36. Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy.
Zlotta AR; Noel JC; Fayt I; Drowart A; Van Vooren JP; Huygen K; Simon J; Schulman CC
J Urol; 1999 Mar; 161(3):792-8. PubMed ID: 10022686
[TBL] [Abstract][Full Text] [Related]
37. Clinical significance of p21-activated kinase 1 expression level in patients with upper urinary tract urothelial carcinoma.
Kuroda K; Asakuma J; Asano T; Horiguchi A; Isono M; Tsujita Y; Sato A; Seguchi K; Ito K; Asano T
Jpn J Clin Oncol; 2015 Jan; 45(1):103-10. PubMed ID: 25324479
[TBL] [Abstract][Full Text] [Related]
38. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
[TBL] [Abstract][Full Text] [Related]
39. Negative p53/positive p21 immunostaining is a predictor of favorable response to chemotherapy in patients with locally advanced bladder cancer.
Koga F; Kitahara S; Arai K; Honda M; Sumi S; Yoshida K
Jpn J Cancer Res; 2000 Apr; 91(4):416-23. PubMed ID: 10804290
[TBL] [Abstract][Full Text] [Related]
40. p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder.
Røtterud R; Berner A; Holm R; Skovlund E; Fosså SD
BJU Int; 2001 Aug; 88(3):202-8. PubMed ID: 11488730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
